Severe hepatotoxicity is uncommon following the introduction of Elexacaftor/Tezacaftor/Ivacaftor: A real-world two-years follow-up study of the Danish cystic fibrosis cohort
ALT levels almost normalized, while GGT and ALP levels declined within two years of ETI treatment. Reassuringly, severe hepatotoxicity was rare, suggesting that close monitoring may suffice for managing mild to moderate hepatotoxicity in pwCF.
Authors
- Bibi Uhre Nielsen (ORCID: https://orcid.org/0000-0003-0622-5262)
- Majbritt Jeppesen
- Marianne Nielsine Skov (ORCID: https://orcid.org/0000-0002-2619-0864)
- Daniel Faurholt‐Jepsen (ORCID: https://orcid.org/0000-0001-8561-0155)
- Janne Petersen (ORCID: https://orcid.org/0000-0001-7323-2548)
- Christian Leo‐Hansen (ORCID: https://orcid.org/0000-0003-2004-6404)
- Hanne Vebert Olesen (ORCID: https://orcid.org/0000-0003-4000-210X)
- Thomas Bryrup (ORCID: https://orcid.org/0000-0001-8533-6766)
- Marianne Hørby Jørgensen (ORCID: https://orcid.org/0000-0003-0658-4636)
- Christine Højte
- Tacjana Pressler (ORCID: https://orcid.org/0000-0002-6434-4975)
- Mette Frahm Olsen (ORCID: https://orcid.org/0000-0002-5742-6403)
- Terese L. Katzenstein (ORCID: https://orcid.org/0000-0002-2233-500X)
Institutions
- Aarhus University (DK)
- Frederiksberg Hospital (DK)
- Copenhagen University Hospital (DK)
- Rigshospitalet (DK)
- Danish Pain Research Center (DK)
Publication Details
- Journal
- Journal of Cystic Fibrosis
- Published
- 2025-08-25
- DOI
- https://doi.org/10.1016/j.jcf.2025.08.008
- Citations
- 3
- Primary Topic
- Cystic Fibrosis Research Advances
- Type
- article
- Field-Weighted Citation Impact
- 4.56
Funders
- Vertex Pharmaceuticals
- Rigshospitalet